TY - JOUR
T1 - Recurrent Gastrointestinal Bleeding in a Middle-Aged Man
AU - Gowani, Faaria
AU - Phillips, Bonnie
AU - Leveque, Christopher
AU - Castillo, Brian
AU - Chen, Jian
AU - Chandler, Wayne
AU - Rice, Lawrence
AU - Salazar, Eric
N1 - Funding Information:
We thank Sasha Pejerrey, PhD, for thorough editorial review. This study was entirely supported by Houston Methodist Hospital.
Publisher Copyright:
© The Author(s) 2021. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved.
© The Author(s) 2021. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Acquired von Willebrand disease (avWD) arises because of mechanisms that destroy, decrease, absorb, or clear von Willebrand factor (vWF). A 59-year-old man presented with a 3-year history of recurrent gastrointestinal bleeding. Laboratory workup revealed a prolonged platelet function assay-100. The vWF antigen was decreased, and a low vWF immunofunctional activity/antigen ratio, low collagen binding/antigen ratio, and decreased intermediate and high molecular weight multimers were noted. The patient had no high-shear stress conditions, and an antibody-mediated process was suspected. A vWF mixing study showed complete correction of vWF activity, suggesting no direct functional inhibitor. The patient was given a bolus of vWF concentrate with serial measurements of vWF; the vWF half-life was 2.5 hours. The vWF propeptide/antigen ratio was 4:1, supporting a diagnosis of aVWD resulting from increased antibody-mediated vWF clearance. This case study emphasizes the laboratory's role in the diagnosis and treatment of rare, overlooked acquired bleeding disorders.
AB - Acquired von Willebrand disease (avWD) arises because of mechanisms that destroy, decrease, absorb, or clear von Willebrand factor (vWF). A 59-year-old man presented with a 3-year history of recurrent gastrointestinal bleeding. Laboratory workup revealed a prolonged platelet function assay-100. The vWF antigen was decreased, and a low vWF immunofunctional activity/antigen ratio, low collagen binding/antigen ratio, and decreased intermediate and high molecular weight multimers were noted. The patient had no high-shear stress conditions, and an antibody-mediated process was suspected. A vWF mixing study showed complete correction of vWF activity, suggesting no direct functional inhibitor. The patient was given a bolus of vWF concentrate with serial measurements of vWF; the vWF half-life was 2.5 hours. The vWF propeptide/antigen ratio was 4:1, supporting a diagnosis of aVWD resulting from increased antibody-mediated vWF clearance. This case study emphasizes the laboratory's role in the diagnosis and treatment of rare, overlooked acquired bleeding disorders.
KW - acquired von Willebrand disease
KW - bleeding disorders
KW - clotting
KW - coagulation
KW - coagulation testing
KW - von Willebrand factor activity testing
KW - Humans
KW - Middle Aged
KW - Gastrointestinal Hemorrhage/complications
KW - Male
KW - von Willebrand Diseases/diagnosis
KW - Platelet Function Tests
KW - Blood Coagulation Tests
KW - von Willebrand Factor
UR - http://www.scopus.com/inward/record.url?scp=85134083628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134083628&partnerID=8YFLogxK
U2 - 10.1093/labmed/lmab104
DO - 10.1093/labmed/lmab104
M3 - Article
C2 - 34940854
AN - SCOPUS:85134083628
SN - 0007-5027
VL - 53
SP - E91-E94
JO - Lab Medicine
JF - Lab Medicine
IS - 4
ER -